Nemolizumab Shows Long-Term Efficacy in Atopic Dermatitis and Prurigo Nodularis

Galderma查看公司主页's nemolizumab查看药品详情 is showing promise as a long-term therapeutic option for patients with atopic dermatitis (搜索)搜索该疾病 and prurigo nodularis (搜索)搜索该疾病, according to new data presented at the 2024 European Academy of Dermatology and Venereology (EADV) congress. The data, from the ARCADIA and OLYMPIA clinical trial programs, highlight the drug's efficacy and safety in treating these chronic skin conditions. Nemolizumab, a targeted inhibitor of IL-31 (搜索)搜索该靶点 signaling, addresses key symptoms such as itch and skin inflammation.

ARCADIA Long-Term Extension Study

The ARCADIA long-term extension study evaluated the safety and efficacy of nemolizumab查看药品详情 over four years in adolescents and adults with moderate-to-severe atopic dermatitis (搜索)搜索该疾病. Patients enrolled from previous phase II and phase III studies received nemolizumab with background topical corticosteroids, with or without topical calcineurin inhibitors.

Interim results at Week 56 demonstrated that patients previously exposed to nemolizumab查看药品详情 in the lead-in study experienced continued improvements in skin lesions compared to when they entered the extension study. Specifically:

• 47% of evaluable patients achieved clear or almost clear skin (IGA score of 0 or 1), up from 29%.
• 73% achieved a 75% improvement in EASI score from their lead-in study baseline, up from 38%.

The data also indicated sustained improvements in itch, sleep, and quality of life, with a consistent safety profile.

Professor Diamant Thaçi, lead investigator of the ARCADIA long-term extension study from the University of Lubeck, Germany, noted, "Many atopic dermatitis (搜索)搜索该疾病 patients struggle to achieve holistic symptom relief with currently available treatments, and the few that do continue to seek treatments with longevity. These new data will add to the growing body of evidence demonstrating the potential long-term benefit of nemolizumab查看药品详情 in atopic dermatitis, with patients seeing improvements in skin lesions, itch, and quality of life outcomes that continue to increase over time, for more than a year."

Biomarker Analysis from ARCADIA Trials

Additional data from the phase III ARCADIA trials revealed that nemolizumab查看药品详情 significantly reduces biomarkers involved in itch, skin lesions, and inflammation. This reduction correlated with improved clinical outcomes, particularly in patients with severe itch, suggesting a greater potential benefit in this subgroup.

OLYMPIA DURABILITY Study

The OLYMPIA DURABILITY study, a 24-week phase IIIb withdrawal study, assessed the long-term efficacy of nemolizumab查看药品详情 in adults with prurigo nodularis (搜索)搜索该疾病. The study included 34 patients who had achieved a clinical response in the OLYMPIA long-term extension study, defined by an IGA score of 0 or 1 and at least a four-point improvement in weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) score from baseline at Week 52.

The study met its primary endpoint, demonstrating that patients continuing nemolizumab查看药品详情 therapy had significantly lower relapse rates (17%) compared to those withdrawn from treatment (75%) after 24 weeks. Relapse was defined as at least a four-point increase in PP-NRS score and/or at least a two-point increase in IGA score from baseline. These findings support the continued use of nemolizumab beyond 52 weeks for patients who are clinical responders.

Professor Franz Legat, lead investigator of the OLYMPIA studies from the Medical University of Graz, Austria, stated, "People living with prurigo nodularis (搜索)搜索该疾病 suffer from chronic, severe itch, which disrupts their quality of life, and visible skin lesions, which can impact their self-confidence. These new long-term data demonstrate that nemolizumab查看药品详情’s efficacy on itch and skin lesions in prurigo nodularis is maintained for over one year, and also show that continuous treatment is necessary to ensure that these burdensome symptoms remain controlled."

Regulatory Status and Future Directions

Nemolizumab查看药品详情 is currently approved in the United States (under the name Nemluvio) for the treatment of adults with prurigo nodularis (搜索)搜索该疾病. The FDA's decision on its use for atopic dermatitis (搜索)搜索该疾病 is expected later this year. Galderma查看公司主页 has also submitted marketing authorization applications for both prurigo nodularis and atopic dermatitis to multiple regulatory authorities worldwide.